Lee Joong-Myung, Sim Young-Suk, Choi Dae-Sung
Department of Orthopaedic Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Hip Pelvis. 2018 Dec;30(4):210-218. doi: 10.5371/hp.2018.30.4.210. Epub 2018 Dec 6.
This is a report on the outcomes associated with a consecutive series of 1,000 cementless hip arthroplasties utilizing the Bencox® hip stem-the first Korean-developed hip prosthesis.
A consecutive series of 1,000 hip arthroplasties using the Bencox® hip stem were analyzed, starting from its initial release (September 2006) until June 2014. Patients in this consecutive series underwent surgery for fractures (n=552), arthritis (n=155), avascular necrosis (n=209), and revisions (n=84). Of these 1,000 cases, patients with a minimum follow-up of at least 1 year (n=616) were retrospectively analyzed for radiographic and clinical outcomes (i.e., Harris hip score). The stability of the prosthesis was evaluated by examining subsidence.
During the follow-up period (mean follow-up period of 54.8 months), there were 2 cases requiring revision of the femoral stem-both were caused by periprosthetic fractures and neither involved stem loosening. The mean Harris hip score during follow-up was 95.5. Bone ongrowth occurred in 95% of patients; no cases of subsidence or aseptic loosening of the stem were detected, and no cases of postoperative complications such as ceramic breakage were observed.
Clinical and radiographic evaluations of hip arthroplasty using the Bencox® hip stem revealed excellent outcomes with an average of 54.8 month follow-up in a consecutive series of 1,000 cases.
本文报告了连续1000例使用Bencox®髋关节柄(韩国首个自主研发的髋关节假体)进行的非骨水泥型髋关节置换术的相关结果。
对从2006年9月首次发布至2014年6月期间连续1000例使用Bencox®髋关节柄的髋关节置换术进行分析。该连续系列中的患者接受手术治疗的病因包括骨折(n = 552)、关节炎(n = 155)、缺血性坏死(n = 209)和翻修手术(n = 84)。在这1000例病例中,对至少随访1年的患者(n = 616)进行回顾性分析,以评估影像学和临床结果(即Harris髋关节评分)。通过检查假体下沉情况评估假体的稳定性。
在随访期间(平均随访期为54.8个月),有2例需要翻修股骨柄,均由假体周围骨折引起,均未涉及柄松动。随访期间Harris髋关节评分的平均值为95.5。95%的患者出现骨长入;未检测到柄下沉或无菌性松动病例,也未观察到陶瓷破裂等术后并发症病例。
对使用Bencox®髋关节柄进行髋关节置换术的临床和影像学评估显示,在连续1000例病例中,平均随访54.8个月,结果优异。